Clinical impact of the accelerate PhenoTest® BC system on patients with gram-negative bacteremia and high risk of antimicrobial resistance: a prospective before-after implementation study

• Váldodahkkit: Tal Brosh-Nissimov (Dahkki), Anka Tzur (Dahkki), Daniel Grupel (Dahkki), Amos Cahan (Dahkki), Nir Ma'aravi (Dahkki), Maya Heled-Akiva (Dahkki), Hasan Jawamis (Dahkki), Hanna Leskes (Dahkki), Erez Barenboim (Dahkki), Nadav Sorek (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: BMC, 2023-07-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Background The Accelerate PhenoTest® BC system (AXDX) is a novel assay for rapid bacterial identification and antimicrobial susceptibility (AST). We report an evaluation of its impact on treatment of patients with Gram-negative bacteremia (GNB) with a high risk of antimicrobial resistance (...